Becton, Dickinson and Company

15 Segment Data

The Company’s organizational structure is based upon its three principal business segments: BD Medical (“Medical”), BD Diagnostics (“Diagnostics”) and BD Biosciences (“Biosciences”).

     The major product lines in the Medical segment include needles, syringes and intravenous catheters, including safety-engineered devices, for medication delivery; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes; prefillable drug delivery devices provided to pharmaceutical companies and sold to end-users as drug/device combinations; surgical blades and regional anesthesia needles; critical care monitoring devices; ophthalmic surgical instruments; sharps disposal containers; and home healthcare products. The major products and services in the Diagnostics segment are integrated systems for specimen collection; an extensive line of safety-engineered specimen blood collection products and systems; plated media; automated blood culturing systems; molecular testing systems for sexually transmitted diseases and healthcare-associated infections; microorganism identification and drug susceptibility systems; and rapid diagnostic assays. The major product lines in the Biosciences segment include fluorescence activated cell sorters and analyzers; cell imaging systems; monoclonal antibodies and kits; reagent systems for life sciences research; tools to aid in drug discovery and growth of tissue and cells; and diagnostic assays.

     The Company evaluates performance of its business segments based upon operating income. Segment operating income represents revenues reduced by product costs and operating expenses.

     Distribution of products is primarily through distributors, as well as directly to hospitals, laboratories and other end-users. Sales to a distributor which supplies the Company’s products to many end users accounted for approximately 11% of revenues in 2006, 2005 and 2004, respectively and included products from the Medical and Diagnostics segments. No other customer accounted for 10% or more of revenues in each of the three years presented.

Revenues(A)	2006			2005			2004
Medical	$	3,203,456		$	2,958,088		$	2,680,165
Diagnostics		1,754,866			1,657,064			1,531,639
Biosciences		876,505			799,529			722,941
	$	5,834,827		$	5,414,681		$	4,934,745
Segment Operating Income
Medical	$	767,672	(B)	$	710,551		$	566,582	(D)
Diagnostics		399,212	(C)		413,908			359,370
Biosciences		213,068			175,339			155,888
Total Segment Operating Income		1,379,952			1,299,798			1,081,840
Unallocated Expenses(E)		(344,995	)(F)		(294,944	)(F)		(328,972	)(G)
Income From Continuing Operations    Before Income Taxes	$	1,034,957		$	1,004,854		$	752,868
Segment Assets
Medical	$	2,835,613		$	2,656,320		$	2,703,643
Diagnostics		1,485,959			1,245,769			1,217,620
Biosciences		727,634			678,286			706,728
Total Segment Assets		5,049,206			4,580,375			4,627,991
Corporate and All Other(H)		1,775,319			1,552,418			1,060,894
Discontinued Operations		—			—			63,694
	$	6,824,525		$	6,132,793		$	5,752,579
Capital Expenditures
Medical	$	270,910		$	184,525		$	158,728
Diagnostics		104,815			99,742			79,782
Biosciences		38,952			22,218			16,560
Corporate and All Other		44,631			11,143			10,648
	$	459,308		$	317,628		$	265,718
Depreciation and Amortization
Medical	$	212,807		$	202,825		$	187,254
Diagnostics		116,072			102,882			97,731
Biosciences		63,383			64,599			55,878
Corporate and All Other		12,833			17,190			16,361
	$	405,095		$	387,496		$	357,224

Revenues by Organizational Units	2006			2005			2004
BD Medical    Medical Surgical Systems	$	1,748,743		$	1,661,150		$	1,540,723
Diabetes Care		753,343			674,020			586,190
Pharmaceutical Systems		639,694			563,271			497,421
Ophthalmic Systems		61,676			59,647			55,831
	$	3,203,456		$	2,958,088		$	2,680,165
BD Diagnostic    Preanalytical Systems	$	927,759		$	854,831		$	787,996
Diagnostic Systems		827,107			802,233			743,643
	$	1,754,866		$	1,657,064		$	1,531,639
BD Biosciences    Immunocytometry Systems	$	502,847		$	452,383		$	397,151
Pharmingen		157,349			140,585			135,650
Discovery Labware		216,309			206,561			190,140
	$	876,505		$	799,529		$	722,941
	$	5,834,827		$	5,414,681		$	4,934,745

Geographic Information
The countries in which the Company has local revenue-generating operations have been combined into the following geographic areas: the United States (including Puerto Rico), Europe, and Other, which is composed of Canada, Latin America, Japan and Asia Pacific.

     Revenues to unaffiliated customers are based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location.

	2006			2005			2004
Revenues    United States	$	2,828,023		$	2,590,951		$	2,435,889
Europe		1,764,600			1,671,112			1,482,793
Other		1,242,204			1,152,618			1,016,063
	$	5,834,827		$	5,414,681		$	4,934,745
Long-Lived Assets    United States	$	1,934,994		$	1,687,808		$	1,687,276
Europe		893,495			823,694			805,179
Other		540,925			424,165			398,453
Corporate		269,858			221,812			220,337
	$	3,639,272		$	3,157,479		$	3,111,245